These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

636 related items for PubMed ID: 18951941

  • 1. DNA based vaccination with a cocktail of plasmids encoding immunodominant Leishmania (Leishmania) major antigens confers full protection in BALB/c mice.
    Ahmed SB, Touihri L, Chtourou Y, Dellagi K, Bahloul C.
    Vaccine; 2009 Jan 01; 27(1):99-106. PubMed ID: 18951941
    [Abstract] [Full Text] [Related]

  • 2. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
    Melby PC, Yang J, Zhao W, Perez LE, Cheng J.
    Infect Immun; 2001 Aug 01; 69(8):4719-25. PubMed ID: 11447143
    [Abstract] [Full Text] [Related]

  • 3. [Immuno-modulating effects of eukaryotic expressing vectors of IL-12 and GM-CSF associated to DNA-based vaccination against experimental cutaneous leishmaniasis in BALB/c mouse].
    Ahmed SB, Dellagi K, Bahloul C.
    Arch Inst Pasteur Tunis; 2009 Aug 01; 86(1-4):39-50. PubMed ID: 20707219
    [Abstract] [Full Text] [Related]

  • 4. Vaccination with plasmid DNA encoding KMPII, TRYP, LACK and GP63 does not protect dogs against Leishmania infantum experimental challenge.
    Rodríguez-Cortés A, Ojeda A, López-Fuertes L, Timón M, Altet L, Solano-Gallego L, Sánchez-Robert E, Francino O, Alberola J.
    Vaccine; 2007 Nov 14; 25(46):7962-71. PubMed ID: 17942199
    [Abstract] [Full Text] [Related]

  • 5. A comparative evaluation of different DNA vaccine candidates against experimental murine leishmaniasis due to L. major.
    Ahmed SB, Bahloul C, Robbana C, Askri S, Dellagi K.
    Vaccine; 2004 Apr 16; 22(13-14):1631-9. PubMed ID: 15068845
    [Abstract] [Full Text] [Related]

  • 6. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
    Iborra S, Soto M, Carrión J, Alonso C, Requena JM.
    Vaccine; 2004 Sep 28; 22(29-30):3865-76. PubMed ID: 15364433
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections.
    Zanin FH, Coelho EA, Tavares CA, Marques-da-Silva EA, Silva Costa MM, Rezende SA, Gazzinelli RT, Fernandes AP.
    Microbes Infect; 2007 Jul 28; 9(9):1070-7. PubMed ID: 17644455
    [Abstract] [Full Text] [Related]

  • 8. Immunization with the cysteine proteinase Ldccys1 gene from Leishmania (Leishmania) chagasi and the recombinant Ldccys1 protein elicits protective immune responses in a murine model of visceral leishmaniasis.
    Ferreira JH, Gentil LG, Dias SS, Fedeli CE, Katz S, Barbiéri CL.
    Vaccine; 2008 Jan 30; 26(5):677-85. PubMed ID: 18160187
    [Abstract] [Full Text] [Related]

  • 9. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
    Iborra S, Carrión J, Anderson C, Alonso C, Sacks D, Soto M.
    Infect Immun; 2005 Sep 30; 73(9):5842-52. PubMed ID: 16113303
    [Abstract] [Full Text] [Related]

  • 10. Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.
    Zadeh-Vakili A, Taheri T, Taslimi Y, Doustdari F, Salmanian AH, Rafati S.
    Vaccine; 2004 May 07; 22(15-16):1930-40. PubMed ID: 15121305
    [Abstract] [Full Text] [Related]

  • 11. Enhancement of immune response induced by DNA vaccine cocktail expressing complete LACK and TSA genes against Leishmania major.
    Ghaffarifar F, Jorjani O, Sharifi Z, Dalimi A, Hassan ZM, Tabatabaie F, Khoshzaban F, Hezarjaribi HZ.
    APMIS; 2013 Apr 07; 121(4):290-8. PubMed ID: 23030526
    [Abstract] [Full Text] [Related]

  • 12. Cysteine proteinase type III is protective against Leishmania infantum infection in BALB/c mice and highly antigenic in visceral leishmaniasis individuals.
    Khoshgoo N, Zahedifard F, Azizi H, Taslimi Y, Alonso MJ, Rafati S.
    Vaccine; 2008 Oct 29; 26(46):5822-9. PubMed ID: 18804512
    [Abstract] [Full Text] [Related]

  • 13. Successful vaccination against Leishmania chagasi infection in BALB/c mice with freeze-thawed Leishmania antigen and Corynebacterium parvum.
    Vilela Mde C, Gomes DC, Marques-da-Silva Ede A, Serafim TD, Afonso LC, Rezende SA.
    Acta Trop; 2007 Oct 29; 104(2-3):133-9. PubMed ID: 17919443
    [Abstract] [Full Text] [Related]

  • 14. Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice.
    Campos-Neto A, Webb JR, Greeson K, Coler RN, Skeiky YA, Reed SG.
    Infect Immun; 2002 Jun 29; 70(6):2828-36. PubMed ID: 12010969
    [Abstract] [Full Text] [Related]

  • 15. Transmission blocking vaccine studies in leishmaniasis: II. Effect of immunisation using Leishmania major derived 63 kilodalton glycoprotein, lipophosphoglycan and whole parasite antigens on the course of L. major infection in BALB/c mice.
    Tonui WK, Mbati PA, Anjili CO, Orago AS, Turco SJ, Githure JI, Koech DK.
    East Afr Med J; 2001 Feb 29; 78(2):90-2. PubMed ID: 11682953
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Comparative study of DNA vaccines encoding various antigens against Leishmania mexicana.
    Dumonteil E, Andrade-Narvarez F, Escobedo-Ortegon J, Ramirez-Sierra MJ, Valencia-Pacheco G, Flores-Serrano A, Canto-Lara S, Arjona-Torres A.
    Dev Biol (Basel); 2000 Feb 29; 104():135-41. PubMed ID: 11713811
    [Abstract] [Full Text] [Related]

  • 19. Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis.
    Mizbani A, Taheri T, Zahedifard F, Taslimi Y, Azizi H, Azadmanesh K, Papadopoulou B, Rafati S.
    Vaccine; 2009 Dec 10; 28(1):53-62. PubMed ID: 19818721
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.